FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281392> ?p ?o ?g. }

• W4379281392 endingPage "e20613" @default.
• W4379281392 startingPage "e20613" @default.
• W4379281392 abstract "e20613 Background: Lung cancer is the leading cancer mortality worldwide. Radiotherapy(RT) plays an important role in lung cancer treatment. Different does fractionation of RT has different effects on the prognosis of lung cancer. For example, stereotactic body radiotherapy can significantly improve the prognosis compared with conventionally Fractionated Radiotherapy. In non-small cell lung cancer, we have previously shown that Indoleamine 2,3-dioxygenase 1 (IDO1) metabolites and radiation induced changes had significant effects on long-term survival in patients treated with either Stereotactic body Radiation Therapy of 10Gy fraction size or conventional fractionated radiotherapy of 2Gy fraction size. However, the underlining molecular mechanism is unknown. In this study, we aimed to elaborate the molecular mechanism of such clinical differential effects in the laboratory. Methods: This study applied two dose/fractionation regimens with a similar BED10: 10Gyx1 and 2Gyx8. 10Gyx1 and 2Gyx8 were tested in cell lines of A549, H1299, Calu-1, TC-1 of human and murine NSCLC as well as normal rat cardiomyocyte cell line H9c2, and in vivo (TC-1 implanted C57Bl/6 mice). The mRNA and protein levels of IDO1, p-NF-kB, COX2 from cells and tumor tissues were determined by using qPCR, western blot and immunohistochemistry. Survival outcome was tested by colony formation assay in vitro and tumor growth curve in vivo. Results: In vitro, 10Gyx1 and 2Gyx8 induced IDO1 expression in all tested cell lines and the level of IDO1 expression induced by 10Gyx1 was lower than 2Gyx8. Both 10Gyx1 and 2Gyx8 increased p-NF-kB and COX2 expression and the level induced by 10Gyx1 was lower than 2Gyx8. In tumor bearing mice, two dose/fractionation regimens also induced intratumor IDO1 expression and increased the levels of p-NF-kB and COX2. Interestingly, the increased levels of IDO1, p-NF-kB, COX2 after 10Gyx1 were also significantly lower than 2Gyx8 in vivo. IDO inhibitor synergized with RT and enhanced cell killing efficacy of RT. Conclusions: The findings of this study suggest different does fractionation of RT induced up-regulation of IDO1 through NF-kB/COX2 axis in NSCLC and non-cancerous cell lines, what’s more, hypofractionated radiotherapy 10Gyx1 had less upregulation that of conventionally fractionated radiotherapy 2Gy x8 on IDO1 immune inhibitory pathway. The finding of hypofractionated radiotherapy less immune suppression differ from the traditional belief of more immune stimulation. Our current study provides a rationale in using IDO1 as a biomarker to design RT dose fractionation and/or immunotherapy in combination and possibilities for clinical trials to design IDO1 inhibitors in combination with radiotherapy." @default.
• W4379281392 created "2023-06-05" @default.
• W4379281392 creator A5013512280 @default.
• W4379281392 creator A5016183089 @default.
• W4379281392 creator A5023016929 @default.
• W4379281392 creator A5043954052 @default.
• W4379281392 creator A5077963200 @default.
• W4379281392 creator A5085285424 @default.
• W4379281392 creator A5085950469 @default.
• W4379281392 creator A5088117306 @default.
• W4379281392 creator A5088290549 @default.
• W4379281392 date "2023-06-01" @default.
• W4379281392 modified "2023-10-18" @default.
• W4379281392 title "Radiation fractionation effect on IDO1 through NF-kB/COX2 axis in non-small cell lung cancer." @default.
• W4379281392 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e20613" @default.
• W4379281392 hasPublicationYear "2023" @default.
• W4379281392 type Work @default.
• W4379281392 citedByCount "0" @default.
• W4379281392 crossrefType "journal-article" @default.
• W4379281392 hasAuthorship W4379281392A5013512280 @default.
• W4379281392 hasAuthorship W4379281392A5016183089 @default.
• W4379281392 hasAuthorship W4379281392A5023016929 @default.
• W4379281392 hasAuthorship W4379281392A5043954052 @default.
• W4379281392 hasAuthorship W4379281392A5077963200 @default.
• W4379281392 hasAuthorship W4379281392A5085285424 @default.
• W4379281392 hasAuthorship W4379281392A5085950469 @default.
• W4379281392 hasAuthorship W4379281392A5088117306 @default.
• W4379281392 hasAuthorship W4379281392A5088290549 @default.
• W4379281392 hasConcept C104317684 @default.
• W4379281392 hasConcept C121608353 @default.
• W4379281392 hasConcept C126322002 @default.
• W4379281392 hasConcept C142724271 @default.
• W4379281392 hasConcept C143998085 @default.
• W4379281392 hasConcept C150903083 @default.
• W4379281392 hasConcept C155806632 @default.
• W4379281392 hasConcept C178790620 @default.
• W4379281392 hasConcept C185592680 @default.
• W4379281392 hasConcept C202751555 @default.
• W4379281392 hasConcept C204232928 @default.
• W4379281392 hasConcept C207001950 @default.
• W4379281392 hasConcept C2776256026 @default.
• W4379281392 hasConcept C2776415932 @default.
• W4379281392 hasConcept C502942594 @default.
• W4379281392 hasConcept C509974204 @default.
• W4379281392 hasConcept C54355233 @default.
• W4379281392 hasConcept C55493867 @default.
• W4379281392 hasConcept C71924100 @default.
• W4379281392 hasConcept C81729549 @default.
• W4379281392 hasConcept C81885089 @default.
• W4379281392 hasConcept C86803240 @default.
• W4379281392 hasConcept C97428945 @default.
• W4379281392 hasConceptScore W4379281392C104317684 @default.
• W4379281392 hasConceptScore W4379281392C121608353 @default.
• W4379281392 hasConceptScore W4379281392C126322002 @default.
• W4379281392 hasConceptScore W4379281392C142724271 @default.
• W4379281392 hasConceptScore W4379281392C143998085 @default.
• W4379281392 hasConceptScore W4379281392C150903083 @default.
• W4379281392 hasConceptScore W4379281392C155806632 @default.
• W4379281392 hasConceptScore W4379281392C178790620 @default.
• W4379281392 hasConceptScore W4379281392C185592680 @default.
• W4379281392 hasConceptScore W4379281392C202751555 @default.
• W4379281392 hasConceptScore W4379281392C204232928 @default.
• W4379281392 hasConceptScore W4379281392C207001950 @default.
• W4379281392 hasConceptScore W4379281392C2776256026 @default.
• W4379281392 hasConceptScore W4379281392C2776415932 @default.
• W4379281392 hasConceptScore W4379281392C502942594 @default.
• W4379281392 hasConceptScore W4379281392C509974204 @default.
• W4379281392 hasConceptScore W4379281392C54355233 @default.
• W4379281392 hasConceptScore W4379281392C55493867 @default.
• W4379281392 hasConceptScore W4379281392C71924100 @default.
• W4379281392 hasConceptScore W4379281392C81729549 @default.
• W4379281392 hasConceptScore W4379281392C81885089 @default.
• W4379281392 hasConceptScore W4379281392C86803240 @default.
• W4379281392 hasConceptScore W4379281392C97428945 @default.
• W4379281392 hasIssue "16_suppl" @default.
• W4379281392 hasLocation W43792813921 @default.
• W4379281392 hasOpenAccess W4379281392 @default.
• W4379281392 hasPrimaryLocation W43792813921 @default.
• W4379281392 hasRelatedWork W1985774067 @default.
• W4379281392 hasRelatedWork W2020692772 @default.
• W4379281392 hasRelatedWork W2348998343 @default.
• W4379281392 hasRelatedWork W2359852078 @default.
• W4379281392 hasRelatedWork W2359858375 @default.
• W4379281392 hasRelatedWork W2360741474 @default.
• W4379281392 hasRelatedWork W2361688476 @default.
• W4379281392 hasRelatedWork W2367427393 @default.
• W4379281392 hasRelatedWork W2407189953 @default.
• W4379281392 hasRelatedWork W2464301138 @default.
• W4379281392 hasVolume "41" @default.
• W4379281392 isParatext "false" @default.
• W4379281392 isRetracted "false" @default.
• W4379281392 workType "article" @default.